Genmab to Receive $50M Milestone After DARZALEX Sales Soar

Genmab will receive a milestone payment of $50 million in its DARZALEX collaboration with Janssen Biotech, Inc.

In August 2012, Genmab granted Janssen the exclusive worldwide license to develop, manufacture and commercialize DARZALEX. Just over 5 years later, Janssen has confirmed that DARZALEX’s sales reached $1 billion in a calendar year, prompting the milestone payment.

“We continue to be pleased with the rapid uptake seen with DARZALEX since its initial launch and approval and are excited to have reached the USD 1 billion sales milestone,” said Jan van de Winkel, Ph.D., chief executive officer of Genmab.